$1.45
At close: Apr 11, 3:59 PM EDT
Comments
Loading...
Innate Pharma Analyst Ratings and Price Targets | OTC:IPHYF | Benzinga
Innate Pharma Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Innate Pharma Corp from these most-recent analyst ratings.
Analyst Ratings for Innate Pharma
| Buy Now | Get Alert | ||||||||
|---|---|---|---|---|---|---|---|---|---|
No data available to display | |||||||||
FAQ
What is the target price for Innate Pharma (IPHYF) stock?
There is no price target for Innate Pharma
What is the most recent analyst rating for Innate Pharma (IPHYF)?
There is no analyst for Innate Pharma
When was the last upgrade for Innate Pharma (IPHYF)?
There is no last upgrade for Innate Pharma
When was the last downgrade for Innate Pharma (IPHYF)?
There is no last downgrade for Innate Pharma.
When is the next analyst rating going to be posted or updated for Innate Pharma (IPHYF)?
There is no next analyst rating for Innate Pharma.
Is the Analyst Rating Innate Pharma (IPHYF) correct?
There is no next analyst rating for Innate Pharma.
Browse analyst ratings and price targets on all stocks.
